Ken Bate, President and Chief Executive Officer
Ken joins Archemix from NitroMed where he served as President and CEO. Previously, Ken held positions as Executive Vice President, Head of Commercial Operations and Chief Financial Officer of Millennium Pharmaceuticals and as Vice President of Sales and Marketing and Chief Financial Officer at Biogen (now Biogen Idec). He is a founding partner of JSB Partners, an investment banking and transaction advisory firm focused on the biopharmaceutical industry. Currently a director of Cubist Pharmaceuticals, Inc. and AVEO Pharmaceuticals Inc., Ken is a graduate of Williams College and The Wharton School of the University of Pennsylvania, where he earned an M.B.A. 
Jim Gilbert, M.D., Senior Vice President, Chief Medical Officer
Jim joined Archemix in September 2006 and is responsible for all clinical and regulatory functions. Before his appointment at Archemix, Jim spent three years with Millennium Pharmaceuticals, most recently as the Vice President of Clinical Development, Cardiovascular/Inflammation. Prior to Millennium, Jim worked at Boehringer Ingelheim Pharmaceuticals Inc., holding numerous positions including Director, Clinical Research, Cardiology. He began his career with Bayer Corporation. Before joining the pharmaceutical industry, Jim held positions as an instructor in the Department of Pharmacology at the University of Connecticut School of Medicine and as a Staff Physician at St. Mary's Hospital in Waterbury, Connecticut. Jim earned an M.D. from the University of Connecticut School of Medicine and a B.S. in Molecular Biophysics and Biochemistry from Yale University. 
Robert Schaub, Ph.D., Senior Vice President, Discovery & Development
Bob has over 25 years of experience in drug discovery and pre-clinical development and is a world-class expert in cardiovascular disease biology. Before his appointment at Archemix, Bob spent 16 years with Genetics Institute and Wyeth Pharmaceuticals, most recently as the Assistant Vice President for Cardiovascular and Metabolic Diseases. In this position he led a research group that identified new disease targets and implemented drug discovery programs and advance molecules to Development Candidate status. During his tenure at Genetics Institute and Wyeth Pharmaceuticals, Bob held numerous other research positions where he had direct responsibility for research programs in inflammation, immunology, oncology, cardiovascular and musculoskeletal diseases. Bob began his career with The Upjohn Company. He received a bachelor's degree in biology from the University of Nevada and a Ph.D. from Washington State University. 
Mark Angelino, Vice President, Pharmaceutical Discovery & Development
Mark joined Archemix Corp. in May of 2008 and currently leads the Pharmaceutical Development function which encompasses all CMC-related activities as well as Discovery Chemistry. His experience spans the regulated environment from development through commercialization including small-molecule, peptide, biologic, and complex-mixture products. Mark joined us from Momenta Pharmaceuticals where he was Senior Director of Development and Manufacturing and was involved in the complex-mixture programs, including the validation and commercial supply chain for generic Lovenox™ and the ANDA submission for generic Copaxone™. Prior to this position, Mark was at Millennium Pharmaceuticals where he was responsible for process development, process engineering, and outsourcing management of all cGMP manufacturing activities for small-molecule, bioconjugate, and biologics programs. While also at Millennium, he made significant contributions to multiple INDs as well as to the sNDA and validation for Integrilin™. Mark has also held positions of increasing responsibility within development and manufacturing at Bristol-Myers Squibb and DuPont Pharmaceuticals. Mark holds a Ph.D. in Chemical Engineering and an M.S. in Chemical Engineering Practice from the Massachusetts Institute of Technology, as well as a B.S. in Chemical Engineering from The Cooper Union. Glenn Goddard, Vice President, Finance
Glenn joined Archemix in 2004 as the Director of Finance. Before joining Archemix, Glenn was the corporate controller of ImmunoGen, Inc., a publicly traded biotechnology company. During his time at ImmunoGen, Glenn was responsible for external financial reporting, financial planning, tax compliance, accounting information systems and initiated the company's SOX compliance efforts. Earlier in his career, Glenn was an audit supervisor within the Technology, Communication and Entertainment group within Ernst & Young and an audit manager at Feeley & Driscoll. Glenn is a graduate of Bentley College, where he earned a Bachelors of Sciences in Accountancy. 
John Harre, J.D., General Counsel & VP Business Development
John joined Archemix in June 2002. John has extensive experience in identifying, obtaining, protecting and maximizing intellectual property in the biotechnology and life sciences sectors. Specific areas of expertise include strategic counseling; development and implementation of worldwide patent strategies; negotiations and drafting complex agreements; providing legal advice on various intellectual property and related matters; advising on FDA-related issues; and all aspects of patent, copyright and trademark litigation. Before joining Archemix, John was a partner in the biotechnology division of Mintz, Levin, Cohn, Ferris, Glovsky & Popeo’s Intellectual Property Section in Boston. Earlier in his legal career, John was a member of the biotechnology patent law divisions at Fish & Richardson in Boston and Sidley, Austin, Brown & Wood in Dallas. John’s undergraduate and graduate work at the University of Missouri and Tennessee, respectively, focused on Biology and Molecular Biology. He received his J.D. from Pierce Law, specializing in intellectual property law. Prior to law school, John spent several years working at various academic, government sponsored and commercial institutions. |
|
